Huizhou Xin Li Tai Pharmaceutical Co. Ltd.

To compare the pharmacokinetic characteristics of single-dose oral benzoate fuxagliptin tablets in patients with different degrees of renal insufficiency and healthy subjects with normal renal function matched by gender, age, and body mass index (BMI). To evaluate the pharmacodynamic characteristics and safety of single-dose oral benzoate fuxagliptin tablets in patients with different degrees of renal insufficiency and healthy subjects with normal renal function.

To evaluate the pharmacokinetic characteristics of fuxagliptin benzoate tablets and glimepiride tablets when used alone or in combination, as well as the safety of the two drugs in combination, and to provide a basis for the clinical application of fuxagliptin.

To evaluate the pharmacokinetic characteristics of fumonisin benzoate tablets and metformin hydrochloride tablets when used alone or in combination, as well as the safety of the two drugs in combination, to provide a basis for the design of dosing regimens in subsequent clinical trials.